Three studies that give hope. Vaccines work better than expected

WITH research conducted by the Scottish Public Health Office (PHS) shows that the Pfizer substance reduces the risk of hospitalization by 85 percent between the 28th and 34th day after the first dose. AstraZeneca’s “Oxford” vaccine reduces the risk of being in hospital by up to 94 percent four weeks after the first dose.

Researchers at the University of Edinburgh, together with colleagues from PHS, examined the number of hospitalizations and health status of people who received a single dose of the vaccine and compared them with the number of hospitalizations who were not vaccinated at all. Overall, people over the age of 80 who are more at risk of having the disease had a 81 percent reduction in the risk of being admitted to hospital four weeks after the first dose.

“These results are very encouraging and have given us good reason to be optimistic about the future,” commented the study’s conclusion at the University of Edinburgh and co-director of the Aziz Sheikh study for British commercial television. ITV. “Finally, we have evidence from around the country that vaccination provides protection against hospitalization,” the scientist added. “There is a need to speed up the administration of the first dose worldwide.”

Sheikh pointed out that the results of the study are preliminary and must be subjected to independent scientific review. According to him, similar results can be expected in other countries that are vaccinated with Pfizer / BioNTech and AstraZeneca.

This is the first study to address hospitalization by vaccination at the national level. The researchers conducted the research between December 8 and February 15, when the first dose in Scotland was given to 1.14 million people. That’s about one-fifth of the Scots. Approximately 650,000 people were vaccinated with Pfizer, and half a million of the doses administered came from AstraZenca. About 8,000 people ended up in Scottish hospitals during the study period, but only 58 of them received the first dose of the vaccine, he writes. BBC.

On Monday, the researchers also published a preliminary data from a similar study in England. A study by vaccinated healthcare professionals shows that the first dose of Pfizer / BioNTech reduces the risk of infection by more than 70%. With the second dose, it’s 85 percent. It also reduces the risk of covid-19 symptoms by 57 percent in people over the age of 80 four weeks after the first dose.

However, despite optimistic data, researchers warn that this is preliminary data and whether vaccination actually prevents the transmission of the disease has yet to be confirmed. Therefore, they do not recommend any mitigation of the existing measures yet.

Here is the latest data from Israel. According to a leaked study to be carried out in collaboration with the Israeli Ministry of Health and Pfizer, Pfizer’s substance appears to reduce disease transmission by up to 89.4 percent. He published the conclusions of the study on his Twitter Israeli journalist Nadav Eyal. According to Bloombergu the result of the study has already been confirmed by a person familiar with its course.

Pfizer / BioNTech said it was still working on data analysis from Israel and declined to comment on the leaked conclusions. However, according to scientists, it should be remembered that vaccinated people are less tested. The resulting number may be slightly skewed. “We need more evidence to find out exactly how much vaccination exactly reduces vaccination transmission,” Professor Zoe McLaren of the University of Maryland told Bloomberg. “But we expect that when we take into account the bias, we find that the vaccine actually reduces transmission. That’s great news. “

In addition, two weeks after the second dose of Pfizer, the risk of developing a severe course of the disease decreases by 99.2%, informed on Saturday, the Israeli Ministry of Health. The risk of dying from covid-19 is down 98.9 percent two weeks after both doses, according to the Israeli authorities.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.